NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs CST 101 (Primary) ; ETBX 011 (Primary) ; GI 4000 (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Avelumab; Bevacizumab; Capecitabine; Cyclophosphamide; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
Indications Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors ImmunityBio; NantKwest

13 May 2024 Status changed from active, no longer recruiting to discontinued.
10 Aug 2020 Planned End Date changed from 1 Dec 2018 to 1 Apr 2021.
10 Aug 2020 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com